Testing new medications combined with chemotherapy for advanced colorectal cancer

Plain-English translation of NCT06885385 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether , either alone or combined with another medication called , works well and is safe when given alongside standard chemotherapy (XELOX) for people with advanced colorectal cancer that has a specific genetic marker (MSS/pMMR). You would receive the medication in one of two treatment groups to see how effective this combination approach is compared to what we currently know works.

Most people with this type of advanced colorectal cancer don't respond well to current immunotherapy treatments. This trial is exploring whether these new medications can help more patients by working in a different way, potentially offering hope to those whose cancer hasn't responded to other approaches.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced colorectal adenocarcinoma (stage IV) with a specific genetic marker called MSS or pMMR
you have not received chemotherapy for your advanced cancer before (or if you did receive chemotherapy earlier, it has been more than 12 months since your cancer came back)
you are in overall good health with an ECOG performance score of 0 or 1 (able to carry out most normal activities)
you have at least one tumor that can be measured on imaging scans
you agree to use effective contraception during the study and for 6 months after treatment if you could become pregnant or father a child

You likely don't qualify if…

you have previously received immunotherapy drugs that block PD-1 or PD-L1
you have had major surgery or radiation therapy within 28 days before starting the study
you are currently taking high-dose steroids (more than 10 mg of prednisone per day) or other strong immune-suppressing medications
you received a live vaccine within 28 days before starting the study
the side effects from your previous cancer treatments have not fully resolved

What participation looks like

You would visit the study center regularly to receive intravenous chemotherapy combined with the new medication(s) according to a set schedule. The study involves multiple visits at different cancer centers, ongoing blood tests and scans to monitor how you're responding, and careful tracking of any side effects. Your participation would continue through your treatment cycles and follow-up visits to evaluate how well the treatment is working for your specific type of cancer.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(2 sites)

China

Beijing Cancer Hospital, Beijing, Beijing Municipality

Shanghai Oriental Hospital, Shanghai, Shanghai Municipality